The patient-centric company has a deep and sustainable product portfolio of 18 gene therapy product candidates, including TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. They are focused on both rare and large patient populations and have exclusive options to acquire four additional development programs. Taysha Gene Therapies combines their team's experience in gene therapy drug development and commercialization with the UT Southwestern Gene Therapy Program to efficiently build an extensive AAV gene therapy pipeline. Their goal is to improve patients' lives by eradicating monogenic CNS disease and rapidly translating treatments from bench to bedside.